REGULATORY · COMPETITIVE · INDIA
Dr. Reddy's launches DCGI‑approved semaglutide
Change
The Drugs Controller General of India approved a generic semaglutide injection, which Dr. Reddy’s Laboratories launched as Obeda for Type 2 diabetes.
Why it matters
The DCGI granted approval for a generic semaglutide injection and Dr. Reddy’s launched the product under the brand name Obeda. Obeda is supplied in 2 mg and 4 mg strengths in a pre‑filled disposable pen for once‑weekly subcutaneous administration, with each pen delivering at least four weekly doses. The therapy is priced at Rs 4,200 per month for both strengths. Development and manufacturing, including the active pharmaceutical ingredient and formulation, were carried out in‑house, and the company intends to seek regulatory approvals to introduce the product in additional countries.
Implications
- · Provides an approved, domestically manufactured GLP‑1 product for procurement by Indian public and private health systems and pharmacies.
- · Requires pharmacies and distributors to stock once‑weekly pre‑filled pen formats in two strengths and manage associated inventory and dosing workflows.
- · Establishes a market price point of Rs 4,200 per month for the offered dosing options that procurement and reimbursement officials can reference.
Who is affected
- · Endocrinologists and diabetologists
- · Retail and hospital pharmacies and distributors
- · Procurement and reimbursement officials in Indian public and private health systems
Source
Topics
Law & Public Safety Regulatory Actions Health & Medicine Pharma & Biotech Healthcare Systems